AAPL337.39-7.24 (-2.10%) ▼|ABBV288.90-5.99 (-2.03%) ▼|ABT109.79+3.59 (+3.38%) ▲|ACN261.94+3.70 (+1.43%) ▲|ADBE252.01+1.78 (+0.71%) ▲|AMAT378.43-11.66 (-2.99%) ▼|AMD472.49-32.31 (-6.40%) ▼|AMGN467.83+1.82 (+0.39%) ▲|AMT188.27+0.49 (+0.26%) ▲|AMZN248.18+7.83 (+3.26%) ▲|AVGO325.90-0.18 (-0.06%) ▼|AXP329.70+10.59 (+3.32%) ▲|BA175.67+4.12 (+2.40%) ▲|BAC49.81-0.20 (-0.40%) ▼|BKNG154.37+6.24 (+4.21%) ▲|BLK1,168.40+20.86 (+1.82%) ▲|BMY62.81+0.33 (+0.52%) ▲|BNY148.19+1.08 (+0.73%) ▲|BRK-B554.74+12.25 (+2.26%) ▲|C123.42+1.45 (+1.19%) ▲|CAT613.55-9.20 (-1.48%) ▼|CL97.33+2.04 (+2.14%) ▲|CMCSA23.67+0.45 (+1.92%) ▲|COF211.51+6.66 (+3.25%) ▲|COP147.43-6.60 (-4.28%) ▼|COST1,038.61+26.33 (+2.60%) ▲|CRM226.94-2.23 (-0.97%) ▼|CSCO102.59-1.92 (-1.84%) ▼|CVS89.13-1.12 (-1.24%) ▼|CVX228.27-7.25 (-3.08%) ▼|DE663.29-12.20 (-1.81%) ▼|DHR228.98-3.25 (-1.40%) ▼|DIS113.11+2.17 (+1.96%) ▲|DUK128.30+0.91 (+0.71%) ▲|EMR166.80+1.86 (+1.13%) ▲|FDX319.68+6.40 (+2.04%) ▲|GD372.72+0.13 (+0.03%) ▲|GE315.16+13.36 (+4.43%) ▲|GEV870.82+12.95 (+1.51%) ▲|GILD170.46-0.22 (-0.13%) ▼|GM89.40+2.00 (+2.29%) ▲|GOOG281.17+2.95 (+1.06%) ▲|GOOGL282.42+2.58 (+0.92%) ▲|GS901.65+7.10 (+0.79%) ▲|HD339.94+10.74 (+3.26%) ▲|HON223.63+5.30 (+2.43%) ▲|IBM254.72-3.10 (-1.20%) ▼|INTC60.28-5.48 (-8.33%) ▼|INTU353.03+11.94 (+3.50%) ▲|ISRG436.96+4.95 (+1.15%) ▲|JNJ271.12-2.08 (-0.76%) ▼|JPM340.93+3.89 (+1.15%) ▲|KO95.95+1.87 (+1.98%) ▲|LIN521.88+7.64 (+1.49%) ▲|LLY1,419.18+1.64 (+0.12%) ▲|LMT642.99+6.04 (+0.95%) ▲|LOW217.17+8.10 (+3.87%) ▲|LRCX227.62-11.49 (-4.81%) ▼|MA657.73+19.72 (+3.09%) ▲|MCD264.22+6.10 (+2.36%) ▲|MDLZ66.08+1.14 (+1.76%) ▲|MDT99.07+2.53 (+2.62%) ▲|META610.48-4.51 (-0.73%) ▼|MMM178.46+4.12 (+2.36%) ▲|MO77.01-1.02 (-1.31%) ▼|MRK149.04-0.49 (-0.32%) ▼|MS186.15+1.85 (+1.00%) ▲|MSFT512.34-9.57 (-1.83%) ▼|MU838.73-46.01 (-5.20%) ▼|NEE85.22+1.51 (+1.80%) ▲|NFLX62.39+0.31 (+0.49%) ▲|NKE39.17+0.50 (+1.28%) ▲|NOW106.76+1.64 (+1.56%) ▲|NVDA203.93-0.72 (-0.35%) ▼|ORCL120.20-10.47 (-8.01%) ▼|PEP139.85+2.51 (+1.83%) ▲|PFE30.91+0.39 (+1.28%) ▲|PG163.80+2.23 (+1.38%) ▲|PLTR181.57-2.54 (-1.38%) ▼|PM207.77-1.02 (-0.49%) ▼|QCOM164.10-0.69 (-0.42%) ▼|RTX202.53+2.73 (+1.37%) ▲|SBUX104.58+0.93 (+0.89%) ▲|SCHW88.88+0.83 (+0.94%) ▲|SO94.49+0.78 (+0.83%) ▲|SPG222.66+4.91 (+2.25%) ▲|T21.45+0.04 (+0.16%) ▲|TMO685.17-11.83 (-1.70%) ▼|TMUS159.14+2.70 (+1.73%) ▲|TSLA403.37+3.56 (+0.89%) ▲|TXN306.78+5.94 (+1.97%) ▲|UBER66.74+1.49 (+2.28%) ▲|UNH401.58-5.40 (-1.33%) ▼|UNP307.37+3.37 (+1.11%) ▲|UPS109.65+1.40 (+1.29%) ▲|USB60.50+1.05 (+1.77%) ▲|V425.74+12.15 (+2.94%) ▲|VZ45.10+0.37 (+0.82%) ▲|WFC85.75+2.35 (+2.82%) ▲|WMT127.33+3.82 (+3.09%) ▲|XOM180.48-6.77 (-3.62%) ▼|AAPL337.39-7.24 (-2.10%) ▼|ABBV288.90-5.99 (-2.03%) ▼|ABT109.79+3.59 (+3.38%) ▲|ACN261.94+3.70 (+1.43%) ▲|ADBE252.01+1.78 (+0.71%) ▲|AMAT378.43-11.66 (-2.99%) ▼|AMD472.49-32.31 (-6.40%) ▼|AMGN467.83+1.82 (+0.39%) ▲|AMT188.27+0.49 (+0.26%) ▲|AMZN248.18+7.83 (+3.26%) ▲|AVGO325.90-0.18 (-0.06%) ▼|AXP329.70+10.59 (+3.32%) ▲|BA175.67+4.12 (+2.40%) ▲|BAC49.81-0.20 (-0.40%) ▼|BKNG154.37+6.24 (+4.21%) ▲|BLK1,168.40+20.86 (+1.82%) ▲|BMY62.81+0.33 (+0.52%) ▲|BNY148.19+1.08 (+0.73%) ▲|BRK-B554.74+12.25 (+2.26%) ▲|C123.42+1.45 (+1.19%) ▲|CAT613.55-9.20 (-1.48%) ▼|CL97.33+2.04 (+2.14%) ▲|CMCSA23.67+0.45 (+1.92%) ▲|COF211.51+6.66 (+3.25%) ▲|COP147.43-6.60 (-4.28%) ▼|COST1,038.61+26.33 (+2.60%) ▲|CRM226.94-2.23 (-0.97%) ▼|CSCO102.59-1.92 (-1.84%) ▼|CVS89.13-1.12 (-1.24%) ▼|CVX228.27-7.25 (-3.08%) ▼|DE663.29-12.20 (-1.81%) ▼|DHR228.98-3.25 (-1.40%) ▼|DIS113.11+2.17 (+1.96%) ▲|DUK128.30+0.91 (+0.71%) ▲|EMR166.80+1.86 (+1.13%) ▲|FDX319.68+6.40 (+2.04%) ▲|GD372.72+0.13 (+0.03%) ▲|GE315.16+13.36 (+4.43%) ▲|GEV870.82+12.95 (+1.51%) ▲|GILD170.46-0.22 (-0.13%) ▼|GM89.40+2.00 (+2.29%) ▲|GOOG281.17+2.95 (+1.06%) ▲|GOOGL282.42+2.58 (+0.92%) ▲|GS901.65+7.10 (+0.79%) ▲|HD339.94+10.74 (+3.26%) ▲|HON223.63+5.30 (+2.43%) ▲|IBM254.72-3.10 (-1.20%) ▼|INTC60.28-5.48 (-8.33%) ▼|INTU353.03+11.94 (+3.50%) ▲|ISRG436.96+4.95 (+1.15%) ▲|JNJ271.12-2.08 (-0.76%) ▼|JPM340.93+3.89 (+1.15%) ▲|KO95.95+1.87 (+1.98%) ▲|LIN521.88+7.64 (+1.49%) ▲|LLY1,419.18+1.64 (+0.12%) ▲|LMT642.99+6.04 (+0.95%) ▲|LOW217.17+8.10 (+3.87%) ▲|LRCX227.62-11.49 (-4.81%) ▼|MA657.73+19.72 (+3.09%) ▲|MCD264.22+6.10 (+2.36%) ▲|MDLZ66.08+1.14 (+1.76%) ▲|MDT99.07+2.53 (+2.62%) ▲|META610.48-4.51 (-0.73%) ▼|MMM178.46+4.12 (+2.36%) ▲|MO77.01-1.02 (-1.31%) ▼|MRK149.04-0.49 (-0.32%) ▼|MS186.15+1.85 (+1.00%) ▲|MSFT512.34-9.57 (-1.83%) ▼|MU838.73-46.01 (-5.20%) ▼|NEE85.22+1.51 (+1.80%) ▲|NFLX62.39+0.31 (+0.49%) ▲|NKE39.17+0.50 (+1.28%) ▲|NOW106.76+1.64 (+1.56%) ▲|NVDA203.93-0.72 (-0.35%) ▼|ORCL120.20-10.47 (-8.01%) ▼|PEP139.85+2.51 (+1.83%) ▲|PFE30.91+0.39 (+1.28%) ▲|PG163.80+2.23 (+1.38%) ▲|PLTR181.57-2.54 (-1.38%) ▼|PM207.77-1.02 (-0.49%) ▼|QCOM164.10-0.69 (-0.42%) ▼|RTX202.53+2.73 (+1.37%) ▲|SBUX104.58+0.93 (+0.89%) ▲|SCHW88.88+0.83 (+0.94%) ▲|SO94.49+0.78 (+0.83%) ▲|SPG222.66+4.91 (+2.25%) ▲|T21.45+0.04 (+0.16%) ▲|TMO685.17-11.83 (-1.70%) ▼|TMUS159.14+2.70 (+1.73%) ▲|TSLA403.37+3.56 (+0.89%) ▲|TXN306.78+5.94 (+1.97%) ▲|UBER66.74+1.49 (+2.28%) ▲|UNH401.58-5.40 (-1.33%) ▼|UNP307.37+3.37 (+1.11%) ▲|UPS109.65+1.40 (+1.29%) ▲|USB60.50+1.05 (+1.77%) ▲|V425.74+12.15 (+2.94%) ▲|VZ45.10+0.37 (+0.82%) ▲|WFC85.75+2.35 (+2.82%) ▲|WMT127.33+3.82 (+3.09%) ▲|XOM180.48-6.77 (-3.62%) ▼|
19.6 C
New York
Monday, November 2, 2026

Tag: proteinuria

newsFORsourcecompanycontentinformationreleases1market

Sobi to present new Aspaveli®/Empaveli® data at ASN Kidney Week 2026

STOCKHOLM, Oct. 19, 2026 /PRNewswire/ -- Sobi® today announced that seven abstracts on Aspaveli/Empaveli (pegcetacoplan) have been accepted for presentation at the American Society...

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio

New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse...

Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026

Findings from the Phase 3 LITESPARK-011 and LITESPARK-012 studies reflect continued research into LENVIMA® (lenvatinib)-based combination regimens for patients with advanced renal cell carcinomaExploratory...

Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF Options

FILKRI is available with a permanent Q-code, standardizing the billing and reimbursement process across all sites of care.RALEIGH, N.C., Oct. 12, 2026 /PRNewswire/ -- Accord...

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®

AHMEDABAD, India, Aug. 7, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as...

Everest Medicines Announces Full Approval of NEFECON® in Taiwan

SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of...

As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProteinuria

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers